Immunology
Sjögren's Syndrome
2
Pipeline Programs↗
6
Active Trials↗
6
Companies Involved↗
Sjögren's Syndrome is an early-stage landscape with 2 programs across 6 companies. The most active players are Kissei Pharmaceutical Co., Ltd., Guangdong ProCapZoom Biosciences Co., Ltd., Otsuka.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
19
clinical trials
Completed7 · 37%
Recruiting4 · 21%
Unknown status4 · 21%
Terminated2 · 11%
Not yet recruiting2 · 11%
Clinical Trials
Trial Activity
19 trials
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Completed·—·Phase 3·NCT04819269·203 enrolled
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01552681·52 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)